Related Experiment Video
Updated: May 8, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Risperidone-induced acromegaly: a case report
Therapeutic Advances in Psychopharmacology
|August 29, 2013
Summary
Newer antipsychotics offer fewer movement issues than older drugs but can cause endocrine side effects. This case study highlights a patient with pituitary macroadenoma linked to long-term risperidone use for schizophrenia.
Area of Science:
- Endocrinology
- Neuroscience
- Pharmacology
Background:
- First-generation antipsychotics (FGAs) are largely replaced by second-generation antipsychotics (SGAs) due to fewer movement disorder side effects.
- SGAs, while superior in managing motor side effects, have shown a notable increase in endocrine-related adverse events in recent years.
Purpose of the Study:
- To present a case of pituitary macroadenoma in a patient diagnosed with paranoid schizophrenia.
- To examine the potential link between long-term risperidone treatment and the development of pituitary macroadenoma.
Main Methods:
- A comprehensive review of the patient's medical history, focusing on 14 years of risperidone treatment for paranoid schizophrenia.
- Literature review on endocrine side effects of second-generation antipsychotics, specifically focusing on pituitary-related issues.
Main Results:
- The patient, a 32-year-old female, developed pituitary macroadenoma during long-term treatment with risperidone.
- This case highlights a potential, albeit rare, endocrine complication associated with second-generation antipsychotic use.
Conclusions:
- Endocrine side effects, including pituitary macroadenoma, are a significant concern with long-term use of second-generation antipsychotics like risperidone.
- Further research is warranted to understand the mechanisms and prevalence of these endocrine complications.
Related Concept Videos
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Cushing Syndrome I: Introduction
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...